Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03829436
Title TPST-1120 as Monotherapy and in Combination With (Nivolumab, Docetaxel or Cetuximab) in Subjects With Advanced Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Tempest Therapeutics

Advanced Solid Tumor



Nivolumab + TPST-1120

Docetaxel + TPST-1120

Cetuximab + TPST-1120

Age Groups: senior | adult
Covered Countries USA

No variant requirements are available.